| 학회지 검색 | HOME > 논문 및 학회지 > 학회지 검색 |
대한생식의학회지 제28권 제4호 2010년
GnRH Antagonist (Cetrotide) Short Protocol의 임상적 유용성에 관한 연구
인제대학교 의과대학 일산백병원 산부인과학교실
김문영, 김문영,정병준
A Study for GnRH Antagonist (Cetrotide) Short Protocol in Controlled Ovarian Hyperstimulation
Kim my
Department of Obstetrics and Gynecology, College of Medicine, Inje University, Ilsan Paik Hospital
Objective: The aim of this study was to evaluate the outcome the GnRH antagonist (Cetrotide) short protocol in controlled ovarian hyperstimulation comparing with GnRH agonist long protocol. Materials and Method: From July 2000 to November 2001, 26 patients, 28 cycles were performed in controlled ovarian hyperstimulation by GnRH antagonist and GnRH agonist. GnRH antagonist (Cetrotide) was administered in 12 patients (14 cycles, Group 1) and GnRH agonist (Lucrin, Sub Q, Group 2) in 14 patients (14 cycles). Ovulation induction was performed by hMG (Pergonal) in group 1, and by Combo (Metrodine HP + Pergonal) in group 2. We compared the fertilization rate, good quality embryo, and clinical pregnancy rate between the two groups. Student-t test and Chi-square were used to determine statistical significance. Statistical significance was defined as p<0.05. Results: Ovarian hyperstimulation syndrome did not occurred in which estradiol (E2) level was 3874¡¾809 pg/ml and the number of retrieved oocytes was 18.4¡¾2.4. The number of used gonadotropin ampules was significantly decreased in Group 1 (26.0 vs. 33.1, p<0.04). There were no significant difference in the number of preovulatory oocyte (10.6¡¾6.9 vs. 10.0¡¾6.1), fertilization rate (74.8¡¾23.4 vs. 72.2¡¾21.8), good quality embryo (58.7¡¾23.6 vs. 38.7¡¾36.6), and embryo transfer (4.3¡¾1.6 vs. 4.4¡¾1.6). Although the age of the group 1 was older than the group 2 (34.4 vs. 30.8), there was no significant difference in clinical pregnancy rate (50.0% vs. 57.1%). Conclusions: We suggest that GnRH antagonist was a safe, effective, and alternative method in the controlled ovarian hyperstimulation, especially in PCOD patients who will be develop the ovarian hyperstimulation syndrome.
키워드 : GnRH antagonist, Ovarian hyperstimulation syndrome
교신저자 : byeongjj@orgio.net
전문 파일 : 
